Adage Capital Partners Gp, L.L.C. Kal Vista Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,419,792 shares of KALV stock, worth $11.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,419,792

Previous 2,050,000 30.74%

Holding current value

$11.9 Million

Previous $24.1 Million 31.92%

% of portfolio

0.03%

Previous 0.05%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $5.96 Million - $9.7 Million	-630,208 Reduced 30.74%	1,419,792 $16.4 Million
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $5.43 Million - $6.56 Million	-525,000 Reduced 20.39%	2,050,000 $24.1 Million
Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $20.7 Million - $30 Million	1,870,000 Added 265.25%	2,575,000 $30.5 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $12.25 $2.67 Million - $4.31 Million	-351,691 Reduced 33.28%	705,000 $8.64 Million
Q3 2023 Nov 14, 2023	SELL	$8.95 - $11.35 $426,449 - $540,804	-47,648 Reduced 4.31%	1,056,691 $10.2 Million
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $309,200 - $422,800	40,000 Added 3.76%	1,104,339 $9.94 Million
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $63,000 - $213,600	-15,000 Reduced 1.39%	1,064,339 $7.19 Million
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $246,250 - $420,749	-25,000 Reduced 2.26%	1,079,339 $15.7 Million
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $1.63 Million - $3.02 Million	200,000 Added 22.12%	1,104,339 $10.9 Million
Q1 2022 May 16, 2022	BUY	$11.2 - $16.97 $224,000 - $339,400	20,000 Added 2.26%	904,339 $13.3 Million
Q3 2021 Nov 15, 2021	SELL	$17.11 - $24.49 $11,309 - $16,187	-661 Reduced 0.07%	884,339 $15.4 Million
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $1.85 Million - $2.39 Million	80,000 Added 9.94%	885,000 $21.2 Million
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $7.42 Million - $21.5 Million	505,000 Added 168.33%	805,000 $20.7 Million
Q4 2020 Feb 16, 2021	SELL	$12.88 - $19.47 $1.29 Million - $1.95 Million	-100,000 Reduced 25.0%	300,000 $5.7 Million
Q1 2020 May 15, 2020	SELL	$5.8 - $18.56 $580,000 - $1.86 Million	-100,000 Reduced 20.0%	400,000 $3.06 Million
Q4 2019 Feb 14, 2020	SELL	$10.31 - $17.81 $2.06 Million - $3.56 Million	-200,000 Reduced 28.57%	500,000 $8.91 Million
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $645,400 - $1.08 Million	35,000 Added 5.26%	700,000 $15.5 Million
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $1.07 Million - $2.02 Million	65,000 Added 10.83%	665,000 $19 Million
Q4 2018 Feb 14, 2019	BUY	$16.21 - $24.06 $4.78 Million - $7.09 Million	294,813 Added 96.6%	600,000 $11.9 Million
Q3 2018 Nov 14, 2018	BUY	$8.0 - $22.11 $2.44 Million - $6.75 Million	305,187 New	305,187 $6.75 Million

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $206M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Kal Vista Pharmaceuticals, Inc. Transaction History